Mouse Monoclonal CHRNA2 Antibody

The CHRNA2 antibody targets the alpha-2 subunit of the nicotinic acetylcholine receptor (nAChR), a ligand-gated ion channel critical for synaptic signaling in the nervous system. Encoded by the CHRNA2 gene, this subunit assembles with other nAChR subunits to form functional receptors that mediate fast neurotransmission by binding acetylcholine. CHRNA2 is primarily expressed in the central nervous system, including the hippocampus, thalamus, and cortex, and is implicated in modulating cognitive functions, reward pathways, and neuronal excitability. Dysregulation of CHRNA2 has been linked to neurological disorders such as epilepsy, schizophrenia, and nicotine addiction. Antibodies against CHRNA2 are essential tools for studying its expression, localization, and function in both physiological and pathological contexts. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to investigate receptor distribution in tissues or cellular models. Additionally, CHRNA2 antibodies aid in exploring genetic mutations or altered receptor activity in disease models, offering insights into potential therapeutic targets. Recent research also highlights their role in characterizing CHRNA2's interaction with neurotoxins or pharmacological agents, advancing drug discovery for neurological conditions. Validated for specificity and sensitivity, these antibodies remain pivotal in bridging molecular studies with clinical applications.